1. Home
  2. EXFY vs NKTX Comparison

EXFY vs NKTX Comparison

Compare EXFY & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Expensify Inc.

EXFY

Expensify Inc.

HOLD

Current Price

$0.75

Market Cap

132.1M

Sector

Technology

ML Signal

HOLD

Logo Nkarta Inc.

NKTX

Nkarta Inc.

HOLD

Current Price

$2.33

Market Cap

132.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXFY
NKTX
Founded
2008
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
132.1M
132.8M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
EXFY
NKTX
Price
$0.75
$2.33
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$4.50
$13.25
AVG Volume (30 Days)
988.5K
646.4K
Earning Date
06-01-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.33
EPS
N/A
N/A
Revenue
$142,101,000.00
N/A
Revenue This Year
$1.21
N/A
Revenue Next Year
$1.05
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.06
N/A
52 Week Low
$0.75
$1.31
52 Week High
$3.60
$2.81

Technical Indicators

Market Signals
Indicator
EXFY
NKTX
Relative Strength Index (RSI) 22.24 48.04
Support Level N/A $1.95
Resistance Level $1.54 $2.41
Average True Range (ATR) 0.08 0.17
MACD -0.02 -0.04
Stochastic Oscillator 2.06 20.49

Price Performance

Historical Comparison
EXFY
NKTX

About EXFY Expensify Inc.

Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app.

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Share on Social Networks: